Polymorphisms of vitamin D receptor gene TaqI susceptibility of prostate cancer: a meta-analysis

Xiawei Fei¹
Nannan Liu²
Huifeng Li¹
Yanting Shen³
Jianming Guo^{1,4}
Zhenqi Wu¹

¹Department of Urology Surgery, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, ²Department of Clinical Laboratory, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu, ³Research Center for Learning Science, Southeast University, Nanjing, ⁴Department of Urology Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai, People's Republic of China

Objective: Many studies have investigated the association of the vitamin D receptor gene TaqI polymorphism with prostate cancer (PCa) risk. However, the evidence is inadequate to draw robust conclusions. To shed light on these inconclusive findings, we conducted a meta-analysis.

Materials and methods: We searched PubMed for eligible articles. The relevant data were abstracted by two independent reviewers with the Stata 11.0 software.

Results: A total of 27 studies were included. The pooled outcomes indicated that the TaqI genetic polymorphisms were significantly associated with the risk of PCa (T vs t allele: odds ratio [OR] = 1.11, 95% confidence interval [CI] = 1.03–1.21, $P=0.008$; TT vs tt: OR = 1.19, 95% CI = 1.01–1.42, $P=0.040$; TT + Tt vs tt: OR = 1.18, 95% CI = 1.02–1.38, $P=0.031$), especially in the Asian population (T vs t allele: OR = 1.11, 95% CI = 1.03–1.21, $P=0.008$; TT/Tt vs tt: OR = 1.93, 95% CI = 1.02–3.66, $P=0.043$). In the tumor stage stratified analyses, the pooled results showed no significant difference in genetic polymorphisms between the local tumor group and the control group or between the local tumor group and the advanced tumor group. However, the genotypes TT and TT/Tt were significantly higher in the advanced PCa group compared to the control group (T vs t allele: OR = 1.20, 95% CI = 1.01–1.42, $P=0.040$; TT vs tt: OR = 1.34, 95% CI = 1.08–1.67, $P=0.009$; TT/Tt vs tt: OR = 1.28, 95% CI = 1.05–1.56, $P=0.015$).

Conclusion: The vitamin D receptor gene TaqI allele polymorphism might be associated with a PCa risk, especially in Asians, which might provide new clues for the pathogenesis research and clinical diagnosis of PCa in the future.

Keywords: vitamin D receptor, polymorphisms, prostate cancer, meta-analysis

Introduction

Prostate cancer (PCa) is the second-most frequently diagnosed cancer in males around the world. It is also one of the leading causes of cancer death among men of all races.¹ Its etiology has remained unclear, and few risk factors have been established for PCa other than older age, a positive family history, and race.² Some previous epidemiological studies suggested that low serum levels of the vitamin D receptor (VDR) might be a risk factor for PCa.^{3,4} Such low levels could be recognized by 1 alpha, 25-dihydroxyvitamin D₃ – active form of vitamin D – and its analogs, and through the interaction between these substances, the tumor cell growth cycle could be fixed in the G1 phase, leading to stagnation of the tumor cells.⁵ However, the mechanism responsible for reduced VDR expression is still not known.

Recently, some studies have shown that VDR gene polymorphisms have functional significance for the stability of mRNA and the protein translation efficiency and may be responsible for the reduced VDR level.^{6,7} The human VDR gene is located on chromosome 12q13.11 and consists of 14 exons spanning ~75 kb.^{8,9} It is highly polymorphic with at least 618 variants reported, most of which are either undetectable or present

Correspondence: Zhenqi Wu
Department of Urology Surgery, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, The Seventh Building 9c, No 1158, East-Park Road, Qingpu District, Shanghai, People's Republic of China
Tel +86 21 6971 9190 ext 7920
Email zhenqi_wu1976@sina.com

at a low frequency in the general population, according to the dbSNP database.¹⁰

TaqI is one of the most extensively studied SNP and is located in exon 9 of the VDR gene. Several previous studies have suggested that TaqI might alter VDR mRNA levels through regulation of mRNA stability and be associated with a PCa risk.¹¹ A number of case-control studies were conducted to investigate the association between the TaqI and the risk of PCa. However, existing evidence is inadequate to draw robust conclusions because the results are not consistent and most studies were generally small. Three published meta-analyses have been reported, but no positive conclusions were given.^{11–13} Subsequently, four new studies have provided additional data on the association between TaqI and PCa risk.^{14–17} Therefore, to shed light on these inconclusive findings, we used the new data to conduct a meta-analysis to revisit the association between the VDR TaqI polymorphism and the risk and characteristics of PCa.

Materials and methods

Search strategy

We searched the PubMed and Web of Science databases up to September 8, 2015, for relevant studies about the association of VDR gene TaqI polymorphism and PCa without language restrictions. The search terms included polymorphism, vitamin D receptor, vitamin D₃ receptor, 1,25-dihydroxyvitamin D₃ receptor, calcitriol receptor, VDR, and PCa, prostate neoplasm, prostate tumor, prostate carcinoma, or prostatic neoplasm.

Inclusion/exclusion criteria

The title, abstract, and full text of the candidate studies were independently screened by two reviewers. A study was included when all of the following criteria were met: 1) A nonfamilial case-control and cohort study that examined the association between VDR polymorphism and PCa risk with genotyping data for TaqI was included. 2) A study that used men with benign prostatic hyperplasia was included, but a study based on family or pedigree was excluded because of consideration of disease specificity and genetic linkage. 3) A study on localized PCa: confined within the prostate, stages T1–T2 or stages A–B; advanced PCa: extraprostatic or metastatic cancer involving lymph nodes or other organs, stages T3–T4 or stages C–D was included. 4) A study that had complete data or data that could be used to calculate an odds ratio (OR) and a 95% confidence interval (95% CI) was included. 5) A study that used men with benign prostatic hyperplasia as a control was included. 6) A case-only study or a study that had incomplete data for the control group was excluded.

Data extraction

Information was carefully extracted from all eligible publications by two independent reviewers (Fei and Liu), based on the aforementioned inclusion criteria. Any disagreements were arbitrated by discussion with a third reviewer (Wu). The following data were collected from each study: the first author's surname, the year of publication, the study location, the ethnicity, the source of the controls, the laboratory methods used to detect VDR TaqI polymorphism, and the number of cases and controls. The ethnic groups were mainly defined as Caucasian, Asian, and African. For analysis of the risk factors associated with PCa, we divided the clinical stages and Gleason score into the following two groups: a local group and an advanced group as described previously, Gleason score <7 and ≥7 groups.

Quality assessment

We used the Newcastle–Ottawa Scale (NOS) to assess the quality of each eligible study. When an item was met, the study got one point. The NOS runs from zero to nine points. A study was considered high quality if it received more than four points.¹⁸

Statistical analysis

The strength of the association between TaqI T/t polymorphism and the risk of PCa was indicated by an OR with a 95% CI. The statistical significance of the pooled OR was assessed with the Z-test and a *P*-value of <0.05 was considered significant. A chi-square-based *Q*-test was conducted to measure the heterogeneity of eligible studies, and the heterogeneity was considered significant if the *P*-value for heterogeneity test was <0.05. Subgroup analyses were conducted to identify the possible variables or characteristics that moderated the obtained results. A sensitivity analysis in which one study was excluded at a time was conducted to evaluate the influence of an individual study based on the results. Begg's funnel plot and Egger's regression test were used to evaluate the publication bias (no publication bias was indicated by a two-sided *P*-value ≥0.05). All analyses were conducted using the Stata version 11.0 software (StataCorp LP, College Station, TX, USA), and a two-sided *P*-value ≥0.05 indicated no significance.

Results

Literature search

The study selection process is shown in Figure 1. The primary literature search identified 507 studies. After the titles and abstracts were screened, 387 studies were excluded; 78 were reviews, meta-analyses, and letters. The full texts of the remaining 42 studies were evaluated further. As a result, 27 studies were included in the meta-analysis.^{3,4,6,14–17,19–38}

Figure 1 Study flowchart for the process of selecting the final 27 studies.

Characters and assessments of involved studies

The 27 eligible studies included 12,276 cases and 13,506 controls and were assessed by the NOS (Table S1). Each had a score of >4 , which means that all the studies had high quality. The distribution of the VDR gene TaqI polymorphism genotype and allele is shown in Tables 1 and S2.

Meta-analysis of the association of VDR gene TaqI polymorphism with PCa risk

The pooled results of 27 relevant studies on the correlation between TaqI polymorphisms and the risk of PCa are presented in Table 2 and Figure 2. The outcome indicated that TaqI genetic polymorphism was significantly associated with the risk of PCa (T vs t allele: OR = 1.11, 95% CI = 1.03–1.21, $P=0.008$; TT vs tt: OR = 1.19, 95% CI = 1.01–1.42, $P=0.040$; TT + Tt vs tt: OR = 1.18, 95% CI = 1.02–1.38, $P=0.031$).

Meta-analysis of the association of VDR gene TaqI polymorphism with PCa risk in different populations

A previous study showed that ethnicity was a primary risk factor for PCa.² In order to draw attention to this point, an stratified analysis of ethnicity was performed,^{3,6,14–17,19–29,31–33,35–38} and the pooled results indicated that TaqI genetic polymorphism

in the VDR gene was closely linked to the pathogenesis of PCa among Asian populations (T vs t allele: OR = 1.11, 95% CI = 1.03–1.21, $P=0.008$; TT/Tt vs tt: OR = 1.93, 95% CI = 1.02–3.66, $P=0.043$) (Table 3 and Figure 3). A sensitivity analyses indicated that an independent study by Jingwi et al was the principal reference for heterogeneity of TaqI polymorphism in the African population.¹⁷ After the exclusion of this study, the heterogeneity was effectively decreased or was eliminated, and the outcome showed that no statistical significance was found among African or Caucasian populations.

Meta-analysis of the association of VDR gene TaqI polymorphism with PCa risk in different tumor stages and Gleason score

We also performed a stratified analysis based on the tumor stage and the Gleason score to delineate the association of VDR gene TaqI polymorphism with PCa risk in more detail. As shown in Table 4 and Figure 4, in the tumor stage stratified analysis, the pooled results showed no significant difference in the genetic polymorphism between local tumor group and the control group or between the local tumor group and the advanced tumor group. However, the genotypes TT and TT/Tt were significantly higher in the advanced

Table 1 Detailed association of VDR TaqI polymorphism with PCa risk in each individual study

Study	OR (95% CI)				
	T allele vs t allele	TT vs tt	TT vs Tt	TT vs (Tt/tt)	(TT/Tt) vs tt
Taylor et al ⁶	1.24 (0.88–1.75)	2.36 (1.01–5.53)	0.67 (0.39–1.54)	0.86 (0.51–1.47)	3.06 (1.41–6.63)
Kibel et al ¹⁹	1.37 (0.73–2.57)	1.69 (0.48–5.93)	1.43 (0.55–3.70)	1.50 (0.62–3.62)	1.41 (0.44–4.51)
Ma et al ²⁰	1.04 (0.86–1.26)	1.09 (0.72–1.63)	1.06 (0.80–1.40)	1.06 (0.81–1.39)	1.05 (0.72–1.53)
Correa-Cerro et al ²¹	1.12 (0.75–1.68)	0.87 (0.37–2.07)	2.00 (1.09–3.68)	1.63 (0.92–2.89)	0.60 (0.27–1.34)
Watanabe et al ²²	1.09 (0.64–1.86)	1.50 (0.30–7.60)	1.00 (0.54–1.87)	1.05 (0.58–1.91)	1.50 (0.30–7.57)
Furuya et al ²³	0.86 (0.45–1.64)	–	0.72 (0.34–1.52)	0.76 (0.36–1.59)	–
Habuchi et al ²⁴	1.22 (0.84–1.78)	1.04 (0.17–6.31)	1.28 (0.85–1.94)	1.27 (0.85–1.91)	0.99 (0.16–5.96)
Blazer et al ²⁵	0.97 (0.66–1.42)	1.06 (0.49–2.31)	0.67 (0.37–1.23)	0.77 (0.43–1.35)	1.33 (0.67–2.67)
Hamasaki et al ³	1.82 (1.09–3.03)	4.00 (0.83–19.35)	1.55 (0.84–2.84)	1.75 (0.98–3.12)	3.62 (0.75–17.39)
Medeiros et al ²⁶	1.11 (0.82–1.49)	1.54 (0.80–2.94)	0.72 (0.46–1.14)	0.86 (0.56–1.33)	1.87 (1.04–3.37)
Gsur et al ²⁷	0.78 (0.58–1.05)	0.57 (0.30–1.06)	0.90 (0.58–1.39)	0.80 (0.53–1.21)	0.60 (0.34–1.07)
Tayeb et al ²⁸	0.90 (0.48–1.68)	0.80 (0.23–2.83)	0.93 (0.35–2.51)	0.89 (0.35–2.27)	0.83 (0.27–2.55)
Tayeb et al ²⁹	4.54 (1.51–13.66)	3.91 (0.43–35.60)	7.42 (1.58–34.90)	6.25 (1.69–23.15)	2.65 (0.29–23.82)
Maistro et al ³⁰	0.74 (0.55–1.01)	0.63 (0.33–1.23)	0.63 (0.41–0.99)	0.63 (0.41–0.96)	0.80 (0.43–1.49)
Bodiwala et al ³¹	1.07 (0.85–1.35)	1.11 (0.68–1.82)	1.17 (0.82–1.67)	1.15 (0.82–1.62)	1.01 (0.65–1.58)
Oakley-Girvan et al ³²	0.92 (0.74–1.16)	0.89 (0.55–1.44)	0.86 (0.61–1.20)	0.86 (0.63–1.19)	0.97 (0.62–1.51)
Huang et al ³³	1.48 (0.76–2.88)	–	1.51 (0.76–3.01)	–	–
John et al ³⁴	1.19 (0.98–1.45)	1.48 (1.00–2.21)	1.07 (0.80–1.44)	1.17 (0.88–1.54)	1.43 (0.99–2.05)
Andersson et al ³⁵	0.99 (0.71–1.36)	0.98 (0.52–1.88)	0.96 (0.58–1.57)	0.97 (0.61–1.53)	1.01 (0.56–1.81)
Chaimuangraj et al ³⁶	1.01 (0.37–2.73)	–	0.87 (0.30–2.55)	0.93 (0.32–2.71)	–
Holick et al ⁴	1.13 (0.95–1.33)	1.15 (0.81–1.63)	1.36 (1.05–1.75)	1.30 (1.02–1.65)	0.97 (0.70–1.33)
Onen et al ³⁷	1.38 (0.98–1.95)	1.81 (0.87–3.78)	1.46 (0.88–2.40)	1.53 (0.96–2.45)	1.49 (0.75–2.96)
Onsory et al ³⁸	1.48 (0.96–2.28)	2.30 (0.72–7.37)	1.54 (0.86–2.74)	1.62 (0.93–2.83)	1.88 (0.61–5.82)
Rowland et al ¹⁴	1.12 (1.00–1.26)	1.283 (1.00–1.64)	1.09 (0.92–1.28)	1.13 (0.97–1.32)	1.23 (0.98–1.55)
Hu et al ¹⁵	0.77 (0.39–1.52)	0.22 (0.20–2.45)	0.96 (0.44–2.11)	0.84 (0.40–1.76)	0.22 (0.02–2.45)
Yousaf et al ¹⁶	1.47 (0.84–2.57)	2.84 (0.92–8.78)	0.30 (0.12–0.75)	0.90 (0.44–1.83)	3.68 (1.22–11.10)
Jingwi et al ¹⁷	1.53 (1.18–1.97)	2.01 (1.12–3.59)	1.68 (1.17–2.40)	1.74 (1.24–2.44)	1.58 (0.91–2.76)

Abbreviations: VDR, vitamin D receptor; PCa, prostate cancer; OR, odds ratio; CI, confidence interval.

PCa group compared to the control group (T vs t allele: OR=1.20, 95% CI=1.01–1.42, $P=0.040$; TT vs tt: OR=1.34, 95% CI=1.08–1.67, $P=0.009$; TT/Tt vs tt: OR=1.28, 95% CI=1.05–1.56, $P=0.015$).

In the Gleason score stratified analysis, no statistically significant difference in the distribution of the allele and genotype of TaqI polymorphism was evident (TT/Tt vs tt: OR=1.28, 95% CI=0.52–3.13, $P=0.584$; TT vs Tt/tt: OR=0.79, 95% CI=0.45–1.37, $P=0.396$). However, the number of articles included^{15,27,30} was too little to draw a robust conclusion. Therefore, further relevant studies should be performed in the future.

Sensitivity analysis

Sensitivity analyses were performed by the sequential omission of individual studies for all subjects and stratified analyses. Except for the stratified analyses of the association between TaqI polymorphism and PCa risk in an African population, the corresponding pooled ORs were not materially altered in the other stratified analyses, indicating the robustness of the results of this meta-analysis.

Publication bias assessment

Begg's funnel plot and Egger's test were performed to assess the publication bias in the literature. No evidence

Table 2 Meta-analysis of the association of VDR gene TaqI polymorphism with PCa risk

Gene	Studies	Test for overall effect			Heterogeneity		Public bias	
		OR (95% CI)	Z-score	P-value	I ²	P-value	Begg's test	Egger's test
T vs t	27	1.11 (1.03–1.21)	2.64	0.008	36.9%	0.029	0.478	0.423
TT vs Tt	27	1.07 (0.94–1.22)	1.05	0.296	49%	0.002	0.835	0.550
TT vs tt	24	1.19 (1.01–1.42)	2.06	0.040	34.4%	0.051	0.673	0.724
TT vs (Tt/Tt)	26	1.10 (0.99–1.24)	1.73	0.084	41.5%	0.015	0.692	0.949
(TT/Tt) vs tt	24	1.18 (1.02–1.38)	2.15	0.031	31.4%	0.072	0.673	0.460

Abbreviations: VDR, vitamin D receptor; PCa, prostate cancer; OR, odds ratio; CI, confidence interval.

Figure 2 (Continued)

Figure 2 ORs of prostate cancer associated with VDR TaqI polymorphisms.

Notes: (A) T vs t, (B) TT vs tt, and (C) (TT/Tt) vs tt. Weights are from random effects analysis.

Abbreviations: OR, odds ratio; VDR, vitamin D receptor; CI, confidence interval.

Table 3 Meta-analysis of the association of VDR gene TaqI polymorphism with PCa risk in different populations

Gene	Studies	Test for overall effect			Heterogeneity		Public bias	
		OR (95% CI)	Z-score	P-value	I ²	P-value	Begg's test	Egger's test
Caucasian								
T vs t	13	1.06 (0.97–1.17)	1.31	0.191	22.9%	0.212	0.583	0.474
TT vs Tt	13	1.02 (0.86–1.21)	0.24	0.898	46.2%	0.034	0.855	0.842
TT vs tt	13	1.14 (0.97–1.33)	1.55	0.122	2.1%	0.425	0.583	0.737
TT vs (tt/Tt)	13	1.04 (0.90–1.21)	0.55	0.579	36.6%	0.090	0.360	0.814
(TT/Tt) vs tt	14	1.13 (0.94–1.35)	1.26	0.208	28.6%	0.150	0.511	0.648
African								
T vs t	5	1.04 (0.85–1.28)	0.42 ^a	0.676 ^a	0.0%	0.956	0.806 ^a	0.917 ^a
TT vs Tt	5	0.97 (0.74–1.29)	0.18 ^a	0.858 ^a	0.0%	0.558	0.221 ^a	0.854 ^a
TT vs tt	5	1.22 (0.75–1.97)	0.80 ^a	0.421 ^a	0.0%	0.844	0.806 ^a	0.935 ^a
TT vs (tt/Tt)	5	1.01 (0.78–1.32)	0.08 ^a	0.933 ^a	0.0%	0.805	0.462 ^a	0.781 ^a
(TT/Tt) vs tt	6	1.32 (0.94–1.87)	1.59	0.112	0.0%	0.808	0.368	0.366
Asian								
T vs t	9	1.27 (1.06–1.52)	2.56	0.010	0.0%	0.527	0.175	0.308
TT vs Tt	9	1.07 (0.81–1.43)	0.49	0.627	39.1%	0.107	0.059	0.088
TT vs tt	6	1.44 (0.59–3.51)	0.80	0.426	59.7%	0.030	0.452	0.969
TT vs (tt/Tt)	8	1.19 (0.96–1.47)	1.58	0.115	0.0%	0.517	0.063	0.153
(TT/Tt) vs tt	6	1.93 (1.02–3.66)	2.02	0.043	11.8%	0.340	0.054	0.067

Note: ^aJingwi et al's study¹⁷ was excluded.

Abbreviations: VDR, vitamin D receptor; PCa, prostate cancer; OR, odds ratio; CI, confidence interval.

of publication bias was found for all analyses. Egger's and Begg's tests were not performed for the Gleason stratified analyses and the stage stratified analyses of TT vs tt in the comparison of local tumor group with the control group and the local tumor group with the advanced tumor group due to the small number of included studies.

Discussion

Various factors contribute to the basic pathology of PCa. Clinical diagnosis of the disease is aided by prostate-specific antigen and biopsy, but none of these methods provide a definitive diagnosis and/or a credible assessment

of progression of the disease.^{39,40} Recently, genetic susceptibility to cancer has been a focus of research by the scientific community. The development and progression of PCa are influenced by vitamin D synthesis.³ Therefore, the polymorphism of genes that encode key proteins involved in vitamin D synthesis and metabolism has been chosen as primary candidate genes for PCa susceptibility. Currently, a growing number of studies that have revealed polymorphic variants of the VDR gene were associated with the etiology of PCa. In this meta-analysis, we have analyzed the role of the VDR gene TaqI polymorphism in PCa, which is located in exon 9 and is responsible for the stability of the mRNA.

Figure 3 (Continued)

Figure 3 ORs of prostate cancer associated with TaqI polymorphism in different populations.

Notes: (A) T vs t and (B) (TT/Tt) vs tt. Weights are from random effects analysis.

Abbreviations: OR, odds ratio; CI, confidence interval.

We found that a variant TaqI allele (t) was significantly correlated with a reduced risk of PCa, suggesting it might be a protective factor for PCa, which was consistent with a previous meta-analysis.¹⁰

Ethnicity is an important biological factor that might influence VDR function through gene–gene interaction. In our analysis, the association of TaqI polymorphism with a PCa risk was observed in the Asian population, which was consistent with Yin et al¹⁰ Although the underlying mechanism for the observed ethnic difference in the PCa risk must still be elucidated, a tumor-protective effect of the TaqI t allele in Asians was significantly more pronounced than

in the other two ethnic groups, Caucasians and Africans. In the Asian population, a tt genotype carrier had a lower risk of PCa, compared to a TT or TT/Tt genotype.

We also performed tumor stage and Gleason score stratified analyses. Differently from Yin et al's study,¹⁰ we obtained some positive results. We found that the t allele and the tt genotype could reduce the PCa risk when compared with the T allele, TT genotype, or TT/Tt genotype, indicating that variant the TaqI t allele might indeed be associated with disease progression. However, the Gleason score stratified analysis indicated no association between TaqI polymorphism and PCa risk.

Table 4 Meta-analysis of the association of VDR gene TaqI polymorphism with PCa risk in different tumor stages

Stage	Studies	Test for overall effect			Heterogeneity		Public bias	
		OR (95% CI)	Z-score	P-value	I ²	P-value	Begg's test	Egger's test
Local vs control								
T vs t	5	1.09 (0.95–1.25)	1.18	0.237	0.0%	0.939	0.806	0.741
TT vs tt	2	1.26 (0.91–1.73)	1.40	0.160	0.0%	0.635	–	–
TT vs Tt	5	0.97 (0.80–1.18)	0.32	0.752	0.0%	0.941	0.806	0.213
TT vs (tt/Tt)	6	1.07 (0.88–1.31)	0.68	0.498	3.3%	0.395	1.000	0.885
(TT/Tt) vs tt	4	1.16 (0.88–1.53)	1.07	0.287	0.0%	0.451	0.734	0.442
Advanced vs control								
T vs t	6	1.20 (1.01–1.42)	2.05	0.040	31.5%	0.199	0.452	0.354
TT vs tt	4	1.34 (1.08–1.67)	0.63	0.009	0.0%	0.746	0.734	0.216
TT vs Tt	6	1.15 (0.86–1.52)	0.93	0.352	45.6%	0.101	0.707	0.799
TT vs (tt/Tt)	7	1.17 (0.89–1.54)	1.14	0.256	43.6%	0.100	0.368	0.941
(TT/Tt) vs tt	6	1.28 (1.05–1.56)	2.44	0.015	0.0%	0.821	0.420	0.189
Local vs advanced								
T vs t	5	0.95 (0.82–1.10)	0.65	0.515	0.0%	0.536	0.462	0.191
TT vs tt	2	1.02 (0.72–1.45)	0.13	0.896	0.0%	0.663	–	–
TT vs Tt	5	0.76 (0.48–1.21)	1.14	0.255	32.9%	0.202	0.806	0.575
TT vs (tt/Tt)	6	0.87 (0.62–1.21)	0.84	0.400	14.0%	0.325	0.260	0.805
(TT/Tt) vs tt	4	1.01 (0.74–1.38)	0.08	0.938	0.0%	0.628	0.734	0.054

Abbreviations: VDR, vitamin D receptor; PCa, prostate cancer; OR, odds ratio; CI, confidence interval.

Figure 4 (Continued)

Figure 4 ORs of TaqI polymorphism comparing advanced prostate cancer group with control group.

Notes: (A) T vs t, (B) TT vs tt, and (C) (TT/Tt) vs tt. Weights are from random effects analysis.

Abbreviations: OR, odds ratio; CI, confidence interval.

Study limitations

Although our study showed some positive results, this meta-analysis had several limitations that should be taken consideration when assessing the results. First, although we performed subgroup analyses stratified by ethnicity, tumor stage, and the Gleason score, heterogeneity of TaqI polymorphism among the studies still exists, which suggested that other potential confounding factors were present in the included studies, such as genotyping error, selection bias, population-specific gene–gene or gene–environment interaction, allelic heterogeneity, and chance.^{41,42} Although evidence for heterogeneity exists, the sensitivity analysis indicated that studies contributing to the heterogeneity did not significantly affect the estimate of the overall OR. Second, the overall outcomes were based on unadjusted effect estimates. Although the cases and controls were matched for age, sex, and residence in all studies, these confounding factors could slightly modify the effective estimates and a more precise evaluation would have to be adjusted for the potentially suspicious factors. Third, benign prostate hyperplasia was used as control in some included studies, which could affect the pooled results to a varying degree. Finally, in some pooled analyses such as Gleason score stratified analysis, the number of included studies was too small, so further relevant studies should be performed in the future so that a stronger conclusion could be drawn.

Conclusion

In summary, a strong association was observed between VDR TaqI genetic polymorphism and PCa, and therefore, TaqI genetic polymorphism may be valuable as a biomarker,

especially in Asians. Considering that the quality and quantity of the reviewed articles were limited, larger, well-designed studies should be used in the future to further confirm the association between TaqI genetic polymorphism and PCa.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Faezeh A, Mehdi KP, Mahsa J, Bahram R. Fruit and vegetable intake in relation to prostate cancer in Iranian men: a case-control study. *Asian Pac J Cancer Prev*. 2014;15:5317–5324.
2. Shavers VL, Underwood W, Moser RP. Race/ethnicity and the perception of the risk of developing prostate cancer. *Am J Prev Med*. 2009;37:64–67.
3. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T. Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. *Endocr J*. 2001;48:543–549.
4. Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, Peters U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. *Cancer Epidemiol Biomarkers Prev*. 2007;16:1990–1999.
5. Hamasaki T, Inatomi H, Katoh T, et al. N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men. *Int J Urol*. 2003;10:167–173.
6. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. *Cancer Res*. 1996;56:4108–4110.
7. Uitterlinden AG, Fang Y, Van Meurs JB, Pol HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. *Gene*. 2004;338:143–156.
8. Miyamoto K, Kesterson RA, Yamamoto H, et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. *Mol Endocrinol*. 1997;11:1165–1179.
9. Crofts LA, Hancock MS, Morrison NA, Eisman JA. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. *Proc Natl Acad Sci U S A*. 1998;95:10529–10534.

10. Yin M, Wei S, Wei QY. Vitamin D receptor genetic polymorphisms and prostate cancer risk: a meta-analysis of 36 published studies. *Int J Clin Exp Med*. 2009;2:159–175.
11. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. *Nature*. 1994;367:284–287.
12. Ntais C, Polycarpou A, Ioannidis JP. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2003;12:1395–1402.
13. Berndt SI, Dodson JL, Huang WY, Nicodemus KK. A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. *J Urol*. 2006;175:1613–1623.
14. Rowland GW, Schwartz GG, John EM, Ingles SA. Protective effects of low calcium intake and low calcium absorption vitamin D receptor genotype in the California Collaborative Prostate Cancer Study. *Cancer Epidemiol Biomarkers Prev*. 2013;22:16–24.
15. Hu J, Qiu Z, Zhang L, Cui F. Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer. *Diagn Pathol*. 2014;22(9):84.
16. Yousaf N, Afzal S, Hayat T, et al. Association of vitamin D receptor gene polymorphisms with prostate cancer risk in the Pakistani population. *Asian Pac J Cancer Prev*. 2014;15:10009–10013.
17. Jingwi EY, Abbas M, Ricks-Santi L, et al. Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men. *Anticancer Res*. 2015;35:1549–1558.
18. Ownby RL, Crocco E, Acevedo A, John V, Loe-wenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and meta-regression analysis. *Arch Gen Psychiatry*. 2006;63:530–538.
19. Kibel AS, Isaacs SD, Isaacs WB, Bova GS. Vitamin D receptor polymorphisms and lethal prostate cancer. *J Urol*. 1998;160:1405–1409.
20. Ma J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. *Cancer Epidemiol Biomarkers Prev*. 1998;7:385–390.
21. Correa-Cerro L, Berthon P, Häussler J, et al. Vitamin D receptor polymorphisms as markers in prostate cancer. *Hum Genet*. 1999;105:281–287.
22. Watanabe M, Fukutome K, Murata M, et al. Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. *Anticancer Res*. 1999;19:4511–4514.
23. Furuya Y, Akakura K, Masai M, Ito H. Vitamin D receptor gene polymorphism in Japanese patients with prostate cancer. *Endocr J*. 1999;46:467–470.
24. Habuchi T, Suzuki T, Sasaki R, et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. *Cancer Res*. 2000;60:305–308.
25. Blazer DG, Umbach DM, Bostick RM, Taylor JA. Vitamin D receptor polymorphisms and prostate cancer. *Mol Carcinog*. 2000;27:18–23.
26. Medeiros R, Morais A, Vasconcelos A, et al. The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. *J Hum Genet*. 2002;47:413–418.
27. Gsur A, Madersbacher S, Haidinger G, et al. Vitamin D receptor gene polymorphism and prostate cancer risk. *Prostate*. 2002;51:30–34.
28. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. *Br J Cancer*. 2003;88:928–932.
29. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. *Saudi Med J*. 2004;25:447–451.
30. Maistro S, Snitcovsky I, Sarkis AS, da Silva IA, Brentani MM. Vitamin D receptor polymorphisms and prostate cancer risk in Brazilian men. *Int J Biol Markers*. 2004;19:245–249.
31. Bodiwala D, Luscombe CJ, French ME, et al. Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. *Environ Mol Mutagen*. 2004;43:121–127.
32. Oakley-Girvan I, Feldman D, Eccleshall TR, et al. Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. *Cancer Epidemiol Biomarkers Prev*. 2004;13:1325–1330.
33. Huang SP, Chou YH, Wayne Chang WS, et al. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. *Cancer Lett*. 2004;207:69–77.
34. John EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. *Cancer Res*. 2005;65:5470–5479.
35. Andersson P, Varenhorst E, Söderkvist P. Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. *Eur J Cancer*. 2006;42:2833–2837.
36. Chaimuangraj S, Thammachoti R, Ongphiphadhanakul B, Thammavit W. Lack of association of VDR polymorphisms with Thai prostate cancer as compared with benign prostate hyperplasia and controls. *Asian Pac J Cancer Prev*. 2006;7:136–139.
37. Onen IH, Ekmekci A, Eroglu M, Konac E, Yesil S, Biri H. Association of genetic polymorphisms in vitamin D receptor gene and susceptibility to sporadic prostate cancer. *Exp Biol Med (Maywood)*. 2008;233:1608–1614.
38. Onsory K, Sobti RC, Al-Badran AI, et al. Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. *Mol Cell Biochem*. 2008;314:25–35.
39. Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. *Urology*. 2000;55:323–327.
40. Harnden P, Naylor B, Shelley MD, Clements H, Coles B, Mason MD. The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. *Cancer*. 2008;112:971–981.
41. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. *Genet Epidemiol*. 2005;28:123–137.
42. Lin PI, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: the flip-flop phenomenon. *Am J Hum Genet*. 2007;80:531–538.

Supplementary materials

Table S1 Characteristics and quality assessment of eligible studies in meta-analysis

Study	Country	Ethnicity	Study design	Genotyping method	Quality indicators from Newcastle–Ottawa Scale	H–w test
Taylor et al ⁶	USA	Caucasian, African	Hospital based	RFLP-PCR	6	Yes
Kibel et al ¹⁹	USA	Caucasian, African	Hospital based	PCR-RFLP	7	Yes
Ma et al ²⁰	USA	Caucasian	Nested in PHS cohort study	PCR-RFLP	7	Yes
Correa-Cerro et al ²¹	Germany	Caucasian	Hospital based	PCR-RFLP	6	Yes
Watanabe et al ²²	Japan	Asian	Hospital based	PCR-RFLP	6	No
Furuya et al ²³	Japan	Asian	Hospital based	PCR-RFLP	6	Yes
Habuchi et al ²⁴	Japan	Asian	Hospital based	PCR-RFLP	6	Yes
Blazer et al ²⁵	USA	Caucasian, African	Community based	PCR-RFLP	8	No
Hamasaki et al ³	Japan	Asian	Hospital based	PCR-RFLP	6	Yes
Medeiros et al ²⁶	Portugal	Caucasian	Hospital based	PCR-RFLP	6	Yes
Gsur et al ²⁷	Austria	Caucasian	Hospital based	PCR-RFLP	7	Yes
Tayeb et al ²⁸	UK	Caucasian	Selected from pathology database	PCR-SSCP	6	Yes
Tayeb et al ²⁹	UK	Caucasian	Hospital based	PCR-RFLP	6	Yes
Maistro et al ³⁰	Brazil	Caucasian, African	Population based	PCR-RFLP	6	Yes
Bodiwala et al ³¹	UK	Caucasian	Hospital based	PCR-RFLP	6	Yes
Oakley-Girvan et al ³²	USA	Caucasian, African	Population based	PCR-RFLP	6	Yes
Huang et al ³³	Taiwan	Asian	Hospital based	PCR-RFLP	6	Yes
John et al ³⁴	USA	Caucasian	Population based	PCR-RFLP	6	Yes
Andersson et al ³⁵	Sweden	Caucasian	Hospital based	PCR-RFLP	6	Yes
Chaimuangraj et al ³⁶	Thailand	Asian	Hospital based	PCR-RFLP	6	Yes
Holick et al ⁴	USA	African, Caucasian	Population based	PCR-SSCP	6	Yes
Onen et al ³⁷	Turkey	Caucasian	Hospital based	PCR-RFLP	6	Yes
Onsory et al ³⁸	India	Indian	Hospital based	PCR-SSCP	6	Yes
Rowland et al ¹⁴	American	African, Caucasian	Population based	PCR-RFLP	6	Yes
Hu et al ¹⁵	People's Republic of China	Asian	Hospital based	Real-time PCR	6	Yes
Yousaf et al ¹⁶	Pakistan	Asian	Hospital based	PCR-SSCP	6	Yes
Jingwi et al ¹⁷	American	Caucasian	Hospital based	Real-time PCR	6	Yes

Abbreviations: H-w, Hardy-Weinberg; RFLP, restriction fragment length polymorphism; PCR, polymerase chain reaction; SSCP, single-strand conformation polymorphism.

Table S2 Distribution of TaqI allele and genotype

Study	Group	Allele			Genotype			
		n	T	t	n	TT	Tt	tt
Taylor et al ⁶	Case	216	130	86	108	31	68	9
	Control	340	187	153	170	54	79	37
Kibel et al ¹⁹	Case	82	54	28	41	19	16	6
	Control	82	48	34	41	15	18	8
Ma et al ²⁰	Case	744	454	290	372	134	186	52
	204 control	1,178	707	471	589	204	299	86
Correa-Cerro et al ²¹	Case	212	135	77	106	48	39	19
	Control	190	116	74	95	32	52	11
Watanabe et al ²²	Case	200	178	22	100	80	18	2
	Control	404	356	48	202	160	36	6
Furuya et al ²³	Case	132	107	25	66	41	25	0
	Control	120	100	20	60	41	18	1
Habuchi et al ²⁴	Case	444	396	48	222	176	44	2
	Control	674	587	87	337	253	81	3
Blazer et al ²⁵	Case	154	88	66	77	24	40	13
	Control	366	212	154	183	68	76	39
Hamasaki et al ³	Case	230	204	26	115	91	22	2
	Control	266	216	50	133	91	34	8

(Continued)

Table S2 (Continued)

Study	Group	Allele			Genotype			
		n	T	t	n	TT	Tt	tt
Medeiros et al ²⁶	Case	324	195	129	162	52	91	19
	Control	412	238	174	206	73	92	41
Gsur et al ²⁷	Case	380	227	153	190	71	85	34
	Control	380	249	131	190	81	87	22
Tayeb et al ²⁸	Case	42	24	18	21	7	10	4
	Control	758	453	305	379	136	181	62
Tayeb et al ²⁹	Case	56	52	4	28	25	2	1
	Control	112	83	29	56	32	19	5
Maistro et al ³⁰	Case	330	202	128	165	60	82	23
	Control	400	272	128	200	95	82	23
Bodiwala et al ³¹	Case	736	444	292	368	133	178	57
	Control	486	285	201	243	80	125	38
Oakley-Girvan et al ³²	Case	690	418	272	345	124	170	51
	Control	584	365	219	292	115	135	42
Huang et al ³³	Case	320	306	14	160	146	14	0
	Control	410	384	26	205	179	26	0
John et al ³⁴	Case	848	528	320	424	164	200	60
	Control	872	506	366	436	153	200	83
Andersson et al ³⁵	Case	274	164	110	137	51	62	24
	Control	352	212	140	176	67	78	31
Chaimuangraj et al ³⁶	Case	56	50	6	28	22	6	0
	Control	148	132	16	74	59	14	1
Holick et al ⁴	Case	1,172	730	442	586	238	254	94
	Control	1,090	648	442	545	188	272	85
Onen et al ³⁷	Case	266	180	86	133	62	56	15
	Control	314	189	125	157	57	75	25
Onsory et al ³⁸	Case	200	150	50	100	55	40	5
	Control	200	134	66	100	43	48	9
Rowland et al ¹⁴	Case	3,252	2,172	1,080	1,626	732	708	186
	Control	2,144	1,376	768	1,072	451	474	147
Hu et al ¹⁵	Case	216	202	14	108	96	10	2
	Control	484	460	24	242	219	22	1
Yousaf et al ¹⁶	Case	88	67	21	44	27	13	4
	Control	238	163	75	119	76	11	32
Jingwi et al ¹⁷	Case	612	451	161	306	170	111	25
	Control	502	325	177	251	105	115	31

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>